← Leaderboards
David Radin
Biostrategies, Lc
$3,550,799
Attributed
$11,026,976
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2010–22$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$11,026,976 · 13
By mechanism
R44$8,363,691 · 4
R43$2,663,285 · 9
Top collaborators
- Carole L. Cramer17 shared
- Walter Acosta10 shared
- Alessandra D'Azzo5 shared
- Jose Marcos Condori1 shared
- Roy Morello1 shared
- Jianfeng Xu1 shared
- Tianhong Yang1 shared
Most similar at Biostrategies, Lc
Same institution · by research overlap
- Walter Acosta$3,031,644
- Tianhong Yang$821,265
- Shivakumar Devaiah Pattada$1,499,034
- Jose Marcos Condori$207,935
Others in their field
Top investigators on “Technology”
- David Heimbrook · Leidos Biomedical Research, Inc.$995,338,451
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$606,570,095
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Richard K. Wilson · Washington University$441,856,657
Research focus
TechnologySmall Business Innovation Research GrantPharmaceutical PreparationsCellsBaseInnovationCostAffectMediatingPlantsDrug Delivery SystemsEnzymesLectinUptakeIn VivoTissuesProductionBrainFamilyMouse ModelOrganBiodistributionMammalian CellHuman Genetics
Grant awards (18)
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS$390,497
R43 · FY2022 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$905,262
R44 · FY2021 · HD
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$1,144,737
R44 · FY2020 · HD
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease$293,232
R43 · FY2019 · HL · contact PI
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,147,007
R44 · FY2018 · NS · contact PI
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,071,897
R44 · FY2018 · NS · contact PI
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme$225,000
R43 · FY2018 · AR · contact PI
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,366,586
R44 · FY2017 · NS · contact PI
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,237,037
R44 · FY2017 · NS · contact PI
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$659,425
R44 · FY2016 · NS · contact PI
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$225,000
R43 · FY2016 · HD · contact PI
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$831,740
R44 · FY2015 · NS · contact PI
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$185,915
R43 · FY2015 · NS · contact PI
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$458,316
R43 · FY2014 · NS · contact PI
Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease$225,000
R43 · FY2014 · NS · contact PI
Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta$223,352
R43 · FY2014 · AR · contact PI
Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease$285,783
R43 · FY2013 · NS · contact PI
A Novel Plant Cell Bio-Production Platform for Therapeutic Proteins$151,190
R43 · FY2010 · GM · contact PI